Immuneering Launches Pancreatic Cancer Advisory Board; Establishment Reflects The Clinical Progress Of IMM-1-104 And Its Promise In Pancreatic Cancer
Immuneering Launches Pancreatic Cancer Advisory Board; Establishment Reflects The Clinical Progress Of IMM-1-104 And Its Promise In Pancreatic Cancer
- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer -
-建立反映了IMM-1-104的临床进展及其在胰腺癌中的前景-
- Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104 -
-继最近在胰腺癌中被认定为孤儿药以及IMM-1-104被认定为一线和二线胰腺癌的Fast Track之后-
CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the formation of its Pancreatic Cancer Advisory Board. The advisory board, which comprises world-renowned oncology clinical researchers, will provide strategic medical and clinical guidance to the company as its pipeline, including lead clinical program IMM-1-104, continues to advance.
马萨诸塞州剑桥，2024年12月19日（GLOBE NEWSWIRE）——寻求为广大癌症患者开发和商业化Universal-RAS/RAF药物的临床阶段肿瘤公司Immuneering Corporation（纳斯达克股票代码：IMRX）今天宣布成立胰腺癌顾问委员会。该顾问委员会由世界知名的肿瘤学临床研究人员组成，随着包括主要临床项目IMM-1-104在内的产品线的持续推进，将为公司提供战略医学和临床指导。
